Phase 2 N=30 Randomized Quadruple-blind Treatment

Topical Capsaicin for Cyclical Vomiting

Cyclical Vomiting

Bottom Line

View on ClinicalTrials.gov: NCT03223350 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2021

Primary outcome: Primary: Nausea Visual Analog Scale — 41; 61 mm

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Capsaicin 0.1% Cream (Drug); Placebos (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Henry Ford Health System
Primary completion: Aug 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Nausea Visual Analog Scale	41; 61	—

Summary

This is a phase 2 randomized controlled trial testing the effect of topical capsaicin for the relieve of nausea and vomiting.

Eligibility Criteria

Inclusion Criteria

suspected cyclical vomiting syndrome / cannabinoid hyperemesis
active severe nausea or vomiting in the emergency department

Exclusion Criteria

pregnant women, children < 18 years, no prior history of similar symptoms, suspected surgical or infectious cause of symptoms, suspected hepatitis or pancreatitis, allergy to capsaicin or hot peppers, chronic use of prescription antiemetic in prior 24 hours, abdominal pain alone (without nausea or vomiting)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03223350). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.